Print Page     Close Window     

SEC Filings

424B3
BIOTIME INC filed this Form 424B3 on 02/04/2019
Entire Document
 

 

 

ASTERIAS BIOTHERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

 

  

Nine Months Ended

September 30,

 
   2018   2017 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(13,748)  $(21,824)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization expense   761    840 
Stock-based compensation   2,060    2,895 
Amortization of intangible assets   2,014    2,014 
Common stock issued for services in lieu of cash   643    858 
Gain from change in fair value of warrant liability   (2,054)   (3,404)
Expense related to distribution warrant extension       2,042 
(Gain)/loss from change in fair value of marketable equity securities   (570)   118 
Loss on disposal of property, plant, and equipment   38    112 
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   340    13 
Other assets   237    595 
Accounts payable, accrued expenses and other current liabilities   (73)   (770)
Deferred rent and lease incentives   315    44 
Deferred grant income       (2,185)
Net cash used in operating activities   (10,037)   (18,652)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property, plant and equipment       (237)
Proceeds from the sale of marketable equity securities   2,738    281 
Net cash provided by investing activities   2,738    44 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from sale of common stock under at-the-market transactions   1,167    8,003 
Financing costs for at-the-market sales   (36)   (238)
Proceeds from exercise of stock options       23 
Repayment of lease liability and capital lease obligation   (414)   (360)
Shares retired to pay for employees’ taxes   (160)    
Net cash provided by financing activities   557    7,428 
           
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH   (6,742)   (11,180)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:          
At beginning of period   13,266    19,800 
At end of period  $6,524   $8,620 
           
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:          
Interest paid during the period  $351   $274 
Fully vested common stock and restricted stock units issued in payment for accrued employee bonuses  $951   $720 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 F-35 

© Copyright BioTime, Inc.